FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washing

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

gton, D.C. 20549	OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burde	en						
hours per response:	0.5						

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed nursuant to Section 16(a) of the Securities Exchange Act of 1934

	-(-).			1 110							mpany Act									
1. Name and Address of Reporting Person* <u>LEIDEN JEFFREY M</u>					<u>V</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]								(Che	ck all applica	onship of Reporting Pers all applicable) Director		on(s) to Issu 10% Ow		
(Last)	(F	irst)	(Middle)		1	<u></u> L	• 10121	1							Officer ( below)	(give title		Other (spelow)	pecify	
C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 06/01/2010														
130 WAVERLY STREET					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc	6. Individual or Joint/Group Filing (Check Applicable					
(Street)														<u> </u>		led by One	Repo	rting Person		
CAMBRI	DGE M	IA	02139												Form fil Person		e than	One Report	ing	
(City)	(S	tate)	(Zip)																	
		Tal	ole I - Nor	า-Deriv	/ativ	e Se	curitie	s Ac	quired	, Dis	posed o	f, or	r Bene	eficially	y Owned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D						Execution			Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amount of Securities Beneficially Owned Following		Form	: Direct   II Indirect   E str. 4)   C	Nature of direct eneficial wnership		
								Code	V Amount			(A) or (D)	Price	Transacti	Reported Transaction(s) (Instr. 3 and 4)		(	Instr. 4)		
			Table II -								osed of, convertib			-	Owned					
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rsion (Month/Day/Year)   Execution Date, (Transaction Code (Instr. Set)				5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amo of Securities Underlying Derivative Securities (Instr. 3 and 4)						s Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title		Amount or Number of Shares	mber					

06/01/2010(1)

05/31/2020

**Explanation of Responses:** 

\$34.24

1. Fully vested.

Stock

Option

Remarks:

Valerie L. Andrews, Attorney-

06/02/2010

20,000

D

In-Fact

20,000

Stock

\*\* Signature of Reporting Person

\$<mark>0</mark>

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/01/2010

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

20,000